Drug Trial Radar · NCT06411899
A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
422
Actual
Start
May 15, 2024
Primary completion
Sep 2, 2025
Study completion May 14, 2026
Sponsor
- Lead sponsor
- MoonLake Immunotherapeutics AGIndustry
- Sponsor type
- Industry
- First posted
- May 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to evaluate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa. Participants will be randomized 2:1 to either sonelokimab or matching placebo up to Week 16.
Conditions
- Hidradenitis Suppurativa
Interventions
SonelokimabDrug
Sonelokimab
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hidradenitis Suppurativa Clinical Response 75Time frame: Week 16
Locations
109 sites in 10 countries. Site status is shown where the registry gives one.
Clinical Site
Los Angeles, California
Clinical Site
Northridge, California
Clinical Site
Sacramento, California
Clinical Site
San Diego, California
Clinical Site
Coral Gables, Florida
Clinical Site
Coral Springs, Florida
Clinical Site
Hollywood, Florida
Clinical Site
Margate, Florida
Clinical Site
Miami, Florida
Clinical Site
Tampa, Florida
Clinical Site
Macon, Georgia
Clinical Site
Sandy Springs, Georgia
Clinical Site
West Dundee, Illinois
Clinical Site
Columbus, Indiana
Clinical Site
New Albany, Indiana
Clinical Site
Louisville, Kentucky
Clinical Site
Metairie, Louisiana
Clinical Site
Boston, Massachusetts
Clinical Site
Boston, Massachusetts
Clinical Site
Dearborn, Michigan
Clinical Site
Warren, Michigan
Clinical Site
Las Vegas, Nevada
Clinical Site
New York, New York
Clinical Site
The Bronx, New York
Clinical Site
Boardman, Ohio
Clinical Site
Dayton, Ohio
Clinical Site
Mayfield Heights, Ohio
Clinical Site
Oklahoma City, Oklahoma
Clinical Site
Charleston, South Carolina
Clinical Site
Nashville, Tennessee
Clinical Site
Frisco, Texas
Clinical Site
Houston, Texas
Clinical Site
Houston, Texas
Clinical Site
South Jordan, Utah
Clinical Site
Forest, Virginia
Clinical Site
Mill Creek, Washington
Clinical SIte
Pleven, Bulgaria
Clinical Site
Sofia, Bulgaria
Clinical Site
Sofia, Bulgaria
Clinical Site
Sofia, Bulgaria
Showing 40 of 109 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.